Peptide-drug conjugates for treatment of neurodegenerative diseases

A conjugated molecule comprising a peptide and a N-methyl-D-aspartate receptor (NMDAR) antagonist, wherein the peptide has at least 85% amino acid sequence identity to SEQ ID NO:1 or wherein the peptide is according to SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8, the peptide being linked to the NMDAR antagonist either directly or through a chemical linker, wherein the NMDAR antagonist is selected from memantine, neramexane, and dizocilpine.

A method of treatment and/or prevention of a neurodegenerative disease in a subject in need thereof, the method comprising the steps of:

• providing a conjugated molecule comprising a peptide and a N-methyl-D-aspartate receptor (NMDAR) antagonist, wherein the peptide has at least 85% amino acid sequence identity to SEQ ID NO:1 or wherein the peptide is according to SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8, the peptide being linked to the NMDAR antagonist either directly or through a chemical linker, wherein the NMDAR antagonist is selected from memantine, neramexane, and dizocilpine;
• administering the conjugated molecule to the subject.

A pharmaceutical composition comprising a conjugated molecule comprising a peptide and a N-methyl-D-aspartate receptor (NMDAR) antagonist, wherein the peptide has at least 85% amino acid sequence identity to SEQ ID NO:1 or wherein the peptide is according to SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8, the peptide being linked to the NMDAR antagonist either directly or through a chemical linker, wherein the NMDAR antagonist is selected from memantine, neramexane, and dizocilpine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.